2018

03/12/2018

Cosmetic treatment indicated to counteract hair loss and thinning

Fidia Farmaceutici held a press conference last week, to announce the imminent release of the Trinov…
26/10/2018
Fidia farmaceutici announces the results of a prospective clinical investigation aimed at assessing…
28/09/2018

COMPANY ANNOUNCEMENT

• Completion of efficacy and tolerability study
• Full-scale production initiated
• Launch in Italy by the end of 2018

Further to previous communications, regarding the development of a hair loss remedy (aka “Brotzu…
12/06/2018

The acquisition gives an added boost to Fidia’s leadership in the national and international ophthalmology market segment

• Sooft is active in the treatment of all major eye conditions through Sooft, Bioos, Glaucoom, OftaH.T.and Neoox trademarks
• The company owns 27 patents, further bolstering Fidia Pharma Group’s already strong portfolio, consisting of more than 1,100 patents, of which over 700 on hyaluronic acid

Abano Terme (PD), June 11, 2018 – Fidia Pharma Group, an Italian multinational company, leader in…
25/04/2018

Poster Title: “Hyaluronan Derivative Hymovis® Increases Cartilage Volume and Type II Collagen Turnover in Osteoarthritis Knee:
Data from MOKHA (MRI, BiOmarkers, Knee, Hymovis®, OsteoArthritis) Study”

• Potential beneficial effect of HYMOVIS® on pain and function
• Structural modifying effect in knee OA with HYMOVIS®

Abano Terme, Italy, April 25, 2018 – Fidia Farmaceutici, a world leader in the research, development…
19/03/2018

Italian pharmaceutical R&D excellence at the 33rd Congress of the European Association of Urology

No new drug treatments for primary or recurrent papillary bladder cancer in 15 years

Oncofid®P-B is a Paclitaxel-Hyaluronan Bioconjugate developed and patented by Fidia farmaceutici, a leading Italian pharmaceutical multinational company

Copenhagen, March 18, 2018 – Fidia farmaceutici today announced the positive results from a phase II…
16/03/2018

Sleep problems may affect performance at work and quality of life, as well as have an impact on some chronic diseases

The “Sleep & Health” Project 2018 focuses on the cardiometabolic comorbidities of insomnia, and si dedicated to GPs and specialists (cardiologists, endocrinologists, geriatric physicians, diabetologists, neurologists, internists, and psychiatrists).

Insomnia and disruption of the sleep-wake cycle start a cascade of events that involve different…
09/03/2018

Poster Title: Articular Cartilage Lubrication by HYADD®4 Reduces Tissue Strains, Chondrocyte Death, and Apoptosis

“This current study is consistent with the idea that hyaluronic acid therapies for arthritis may act in part through a mechanical pathway that preserves viability of chondrocytes at the cartilage surface,” states Dr. Bonassar.*

Florham Park, NJ, March 9, 2018 – Fidia Farmaceutici, a world leader in the research, development…

Health
Products
Website

Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint healthcare
- ophthalmology
- wound care
- dermatology
- neurology
- dermo-aesthetics